{"id":387141,"date":"2020-11-23T16:08:14","date_gmt":"2020-11-23T21:08:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387141"},"modified":"2020-11-23T16:08:14","modified_gmt":"2020-11-23T21:08:14","slug":"regenxbio-to-present-at-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/","title":{"rendered":"REGENXBIO to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">ROCKVILLE, Md.<\/span>, <span class=\"xn-chron\">Nov. 23, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV<sup>\u00ae<\/sup>\u00a0Technology Platform, today announced it will present at the following December investor conferences, which will each be held in a virtual meeting format: <\/p>\n<p>\n        <b><br \/>\n          <span class=\"xn-person\">Piper Sandler<\/span> 32<sup>nd<\/sup> Annual Virtual Healthcare Conference <br \/><\/b><br \/>\n        <b>Fireside Chat: <\/b>Pre-recorded<\/p>\n<p>\n        <b>Evercore ISI 3<sup>rd<\/sup> Annual HealthCONx Conference <br \/><\/b><br \/>\n        <b>Fireside Chat: <\/b><br \/>\n        <span class=\"xn-chron\">Thursday, December 3, 2020<\/span> at <span class=\"xn-chron\">11:45 a.m. ET<\/span><\/p>\n<p>The pre-recorded <span class=\"xn-person\">Piper Sandler<\/span> fireside chat is currently available in the Investors section of REGENXBIO&#8217;s website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2990761-1&amp;h=4172675713&amp;u=http%3A%2F%2Fwww.regenxbio.com%2F&amp;a=www.regenxbio.com\" rel=\"nofollow noopener noreferrer\">www.regenxbio.com<\/a>\u00a0and will be available for approximately 30 days. A live webcast of the Evercore fireside chat can be accessed in the same section of REGENXBIO&#8217;s website, and an\u00a0archived replay will be available for approximately 30 days following the presentation.<\/p>\n<p>\n        <b>About\u00a0REGENXBIO Inc.<\/b>\n      <\/p>\n<p>REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO&#8217;s NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.<\/p>\n<p>\n        <b>Contacts:<\/b>\n      <\/p>\n<p>\n        <span class=\"xn-person\">Tricia Truehart<\/span><br \/>\n        <br \/>Investor Relations and Corporate Communications <br \/>347-926-7709 <br \/><a target=\"_blank\" href=\"mailto:ttruehart@regenxbio.com\" rel=\"nofollow noopener noreferrer\">ttruehart@regenxbio.com<\/a><\/p>\n<p>Investors: <br \/>Eleanor Barisser, 212-600-1902 <br \/><a target=\"_blank\" href=\"mailto:eleanor@argotpartners.com\" rel=\"nofollow noopener noreferrer\">eleanor@argotpartners.com<\/a><\/p>\n<p>Media: <br \/><span class=\"xn-person\">David Rosen<\/span>, 212-600-1902 <br \/><a target=\"_blank\" href=\"mailto:david.rosen@argotpartners.com\" rel=\"nofollow noopener noreferrer\">david.rosen@argotpartners.com<\/a><\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1144\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg\" title=\"(PRNewsfoto\/REGENXBIO Inc.)\" alt=\"(PRNewsfoto\/REGENXBIO Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=PH00968&amp;sd=2020-11-23\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/regenxbio-to-present-at-upcoming-investor-conferences-301178926.html\">http:\/\/www.prnewswire.com\/news-releases\/regenxbio-to-present-at-upcoming-investor-conferences-301178926.html<\/a><\/p>\n<p>SOURCE  REGENXBIO Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH00968&amp;Transmission_Id=202011231605PR_NEWS_USPR_____PH00968&amp;DateId=20201123\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire ROCKVILLE, Md., Nov. 23, 2020 \/PRNewswire\/ &#8212;\u00a0REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV\u00ae\u00a0Technology Platform, today announced it will present at the following December investor conferences, which will each be held in a virtual meeting format: Piper Sandler 32nd Annual Virtual Healthcare Conference Fireside Chat: Pre-recorded Evercore ISI 3rd Annual HealthCONx Conference Fireside Chat: Thursday, December 3, 2020 at 11:45 a.m. ET The pre-recorded Piper Sandler fireside chat is currently available in the Investors section of REGENXBIO&#8217;s website at www.regenxbio.com\u00a0and will be available for approximately 30 days. A live webcast of the Evercore fireside chat can be accessed in the same &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;REGENXBIO to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387141","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>REGENXBIO to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"REGENXBIO to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire ROCKVILLE, Md., Nov. 23, 2020 \/PRNewswire\/ &#8212;\u00a0REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV\u00ae\u00a0Technology Platform, today announced it will present at the following December investor conferences, which will each be held in a virtual meeting format: Piper Sandler 32nd Annual Virtual Healthcare Conference Fireside Chat: Pre-recorded Evercore ISI 3rd Annual HealthCONx Conference Fireside Chat: Thursday, December 3, 2020 at 11:45 a.m. ET The pre-recorded Piper Sandler fireside chat is currently available in the Investors section of REGENXBIO&#8217;s website at www.regenxbio.com\u00a0and will be available for approximately 30 days. A live webcast of the Evercore fireside chat can be accessed in the same &hellip; Continue reading &quot;REGENXBIO to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T21:08:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"REGENXBIO to Present at Upcoming Investor Conferences\",\"datePublished\":\"2020-11-23T21:08:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/\"},\"wordCount\":266,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/\",\"name\":\"REGENXBIO to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\",\"datePublished\":\"2020-11-23T21:08:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/684531\\\/RGNX_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regenxbio-to-present-at-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"REGENXBIO to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"REGENXBIO to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"REGENXBIO to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"PR Newswire ROCKVILLE, Md., Nov. 23, 2020 \/PRNewswire\/ &#8212;\u00a0REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV\u00ae\u00a0Technology Platform, today announced it will present at the following December investor conferences, which will each be held in a virtual meeting format: Piper Sandler 32nd Annual Virtual Healthcare Conference Fireside Chat: Pre-recorded Evercore ISI 3rd Annual HealthCONx Conference Fireside Chat: Thursday, December 3, 2020 at 11:45 a.m. ET The pre-recorded Piper Sandler fireside chat is currently available in the Investors section of REGENXBIO&#8217;s website at www.regenxbio.com\u00a0and will be available for approximately 30 days. A live webcast of the Evercore fireside chat can be accessed in the same &hellip; Continue reading \"REGENXBIO to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T21:08:14+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"REGENXBIO to Present at Upcoming Investor Conferences","datePublished":"2020-11-23T21:08:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/"},"wordCount":266,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/","name":"REGENXBIO to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","datePublished":"2020-11-23T21:08:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/684531\/RGNX_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regenxbio-to-present-at-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"REGENXBIO to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387141"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387141\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}